Li Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Li Li has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Lisa A. Maier
Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, Colorado, USA
3 shared publications - Maneesh Bhargava
Division of Pulmonary, Critical Care and Sleep, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
3 shared publications - Briana Barkes
Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, Colorado, USA
2 shared publications - Danielle O Weise
Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA
2 shared publications - Joshua D. Macaluso
Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, Colorado, USA
2 shared publications Margaret M Mroz
Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, Colorado, USA
2 shared publications
Latest Publications
- Open Access
Comparative Evaluation of DDA- and DIA-Based Proteomic Workflows in Beryllium-Related Lung Disease
We compared traditional data-dependent acquisition mass spectrometry (DDA-MS) with the increasingly adopted data-independent acquisition (DIA-MS) to evaluate their relative utility for large-scale quantitative biofluid proteomics of lung compartments, specifically paired bronchoalveolar lavage (BAL) cells and bronchoalveolar lavage fluid (BALF). Using beryllium-related granulomatous lung disease as a focused model, we analyzed BALF and BAL cells from beryllium-sensitized (BeS) individuals using both acquisition strategies to assess proteome depth, quantitative completeness, and analytical robustness. In BAL cells, 5,640 proteins were identified by DDA-MS and 5,227 by DIA-MS; however, DIA-MS yielded markedly improved quantitative completeness, with 5,178 proteins (∼99%) quantified across all samples compared with 3,539 (∼63%) quantified by DDA-MS. While 3,397 proteins were quantified by both methods, DIA-MS uniquely quantified 1,781 lower-abundance proteins. Proteins identified by both DIA and DDA-MS approaches revealed pathways associated with granulomatous inflammation, including Toll-like receptor, clathrin-mediated endocytosis, sirtuin, and C-type lectin receptor signaling, whereas DIA-MS resolved additional pathways, such as the complement cascade, coagulation system, and JAK/IL–6–type cytokine signaling. In BALF, although more proteins were identified by DDA-MS than by DIA-MS (2,069 vs 1,742), DIA-MS achieved greater quantitative completeness, with 1,695 proteins quantified across all samples compared with 1,050 using DDA-MS, underscoring its suitability for biomarker-oriented analyses in lung fluid compartments. Together, these results support DIA-MS as a robust and sensitive platform for quantitative lung proteomics and discovery of disease-relevant protein signatures.
Open AccessComparative Evaluation of DDA- and DIA-Based Proteomic Workflows in Beryllium-Related Lung Disease
We compared traditional data-dependent acquisition mass spectrometry (DDA-MS) with the increasingly adopted data-independent acquisition (DIA-MS) to evaluate their relative utility for large-scale quantitative biofluid proteomics of lung compartments, specifically paired bronchoalveolar lavage (BAL) cells and bronchoalveolar lavage fluid (BALF). Using beryllium-related granulomatous lung disease as a focused model, we analyzed BALF and BAL cells from beryllium-sensitized (BeS) individuals using both acquisition strategies to assess proteome depth, quantitative completeness, and analytical robustness. In BAL cells, 5,640 proteins were identified by DDA-MS and 5,227 by DIA-MS; however, DIA-MS yielded markedly improved quantitative completeness, with 5,178 proteins (∼99%) quantified across all samples compared with 3,539 (∼63%) quantified by DDA-MS. While 3,397 proteins were quantified by both methods, DIA-MS uniquely quantified 1,781 lower-abundance proteins. Proteins identified by both DIA and DDA-MS approaches revealed pathways associated with granulomatous inflammation, including Toll-like receptor, clathrin-mediated endocytosis, sirtuin, and C-type lectin receptor signaling, whereas DIA-MS resolved additional pathways, such as the complement cascade, coagulation system, and JAK/IL–6–type cytokine signaling. In BALF, although more proteins were identified by DDA-MS than by DIA-MS (2,069 vs 1,742), DIA-MS achieved greater quantitative completeness, with 1,695 proteins quantified across all samples compared with 1,050 using DDA-MS, underscoring its suitability for biomarker-oriented analyses in lung fluid compartments. Together, these results support DIA-MS as a robust and sensitive platform for quantitative lung proteomics and discovery of disease-relevant protein signatures.
- Open Access
Molecular characterisation of progressive pulmonary sarcoidosis: protocol for a longitudinal multi-centre study to develop peripheral blood circulating biomarkers for predicting pulmonary sarcoidosis progression
Introduction Sarcoidosis is a heterogeneous granulomatous disease with highly variable clinical trajectories, yet no validated biomarkers exist to distinguish progressive sarcoidosis (P-sarcoidosis) from non-progressive disease (NP-sarcoidosis). This lack of tractable biomarkers limits early risk stratification and impedes therapeutic decision-making. Preliminary data from our group suggest that P-sarcoidosis and NP-sarcoidosis may be differentiated by blood-derived and peripheral blood mononuclear cell (PBMC)-derived molecular signatures, as well as ex vivo granuloma biogenesis in response to putative disease-causing antigens. This protocol describes a multi-omic study aimed at identifying mechanistically grounded, clinically translatable biomarkers that distinguish P-sarcoidosis from NP-sarcoidosis. Methods and analysis We will perform an integrative proteomic and transcriptomic analysis across three biological compartments: ex vivo granuloma model, PBMCs and plasma. Participants with clinically adjudicated P-sarcoidosis or NP-sarcoidosis will provide blood samples for multi-omic profiling. P-sarcoidosis versus NP-sarcoidosis phenotype will be assessed based on changes in spirometry, diffusing capacity for carbon monoxide, chest radiography and need for treatment for pulmonary symptoms. Patient-reported outcomes will also be recorded. Data-driven computational approaches will be used to identify molecular pathways associated with granuloma formation and disease persistence and to develop a classifier that distinguishes P-sarcoidosis from NP-sarcoidosis. Rigorous internal validation, feature-selection procedures and statistical controls for high-dimensional data will be applied. Candidate biomarkers emerging from multi-compartment integration will be prioritised based on biological coherence, reproducibility and clinical feasibility. Ethics and dissemination The study protocol has been approved by the Biomedical Research Alliance of New York, serving as a single Institutional Review Board (IRB) for the project (IRB # 23–02-503), as well as at National Jewish Health (IRB# HS-4091), University of Minnesota (STUDY00020121/SITE00002051) and The Ohio State University (IRB# 2023X0140). All participants will provide informed consent prior to enrolment. Results will be disseminated through peer-reviewed publications, scientific conferences and presentations to patients and advocacy groups. De-identified datasets and analytic workflows will be shared in accordance with institutional policies and data-sharing agreements.
Open AccessMolecular characterisation of progressive pulmonary sarcoidosis: protocol for a longitudinal multi-centre study to develop peripheral blood circulating biomarkers for predicting pulmonary sarcoidosis progression
Introduction Sarcoidosis is a heterogeneous granulomatous disease with highly variable clinical trajectories, yet no validated biomarkers exist to distinguish progressive sarcoidosis (P-sarcoidosis) from non-progressive disease (NP-sarcoidosis). This lack of tractable biomarkers limits early risk stratification and impedes therapeutic decision-making. Preliminary data from our group suggest that P-sarcoidosis and NP-sarcoidosis may be differentiated by blood-derived and peripheral blood mononuclear cell (PBMC)-derived molecular signatures, as well as ex vivo granuloma biogenesis in response to putative disease-causing antigens. This protocol describes a multi-omic study aimed at identifying mechanistically grounded, clinically translatable biomarkers that distinguish P-sarcoidosis from NP-sarcoidosis. Methods and analysis We will perform an integrative proteomic and transcriptomic analysis across three biological compartments: ex vivo granuloma model, PBMCs and plasma. Participants with clinically adjudicated P-sarcoidosis or NP-sarcoidosis will provide blood samples for multi-omic profiling. P-sarcoidosis versus NP-sarcoidosis phenotype will be assessed based on changes in spirometry, diffusing capacity for carbon monoxide, chest radiography and need for treatment for pulmonary symptoms. Patient-reported outcomes will also be recorded. Data-driven computational approaches will be used to identify molecular pathways associated with granuloma formation and disease persistence and to develop a classifier that distinguishes P-sarcoidosis from NP-sarcoidosis. Rigorous internal validation, feature-selection procedures and statistical controls for high-dimensional data will be applied. Candidate biomarkers emerging from multi-compartment integration will be prioritised based on biological coherence, reproducibility and clinical feasibility. Ethics and dissemination The study protocol has been approved by the Biomedical Research Alliance of New York, serving as a single Institutional Review Board (IRB) for the project (IRB # 23–02-503), as well as at National Jewish Health (IRB# HS-4091), University of Minnesota (STUDY00020121/SITE00002051) and The Ohio State University (IRB# 2023X0140). All participants will provide informed consent prior to enrolment. Results will be disseminated through peer-reviewed publications, scientific conferences and presentations to patients and advocacy groups. De-identified datasets and analytic workflows will be shared in accordance with institutional policies and data-sharing agreements.
- 9 April 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (10) , 1431-1439
Immune Regulation by CD55 in Chronic Beryllium Disease
CD55 is an immune regulator that inhibits T cell activation and also binds to CD97, a molecule involved in immune cell migration and signaling. While CD55 expression is reduced in chronic beryllium disease (CBD), its functional role in disease pathogenesis remains unclear. We hypothesized that CD55 downregulation in peripheral blood mononuclear cells (PBMCs) contributes to heightened beryllium (Be)-specific immune responses in CBD. To test this, we characterized CD55 expression and function in PBMCs from individuals with CBD and beryllium sensitization (BeS), as well as in a human Be-specific T cell model. CD55, sCD55, and CD97 mRNA expression were quantified by qRT-PCR in PBMCs from CBD (n = 25), BeS (n = 36), and control (n = 7) subjects. BeSO4 stimulation was used to assess CD55, STAT1, JAK2, and TNF-α expression over time in CBD PBMCs (n = 8). Serum sCD55 was measured by ELISA in an independent cohort. Functional studies using anti-CD55 neutralizing antibodies and the JAK2 inhibitor TG101348 evaluated effects on TNF-α production and lymphocyte proliferation (BeLPT) in PBMCs, and IL-2 production in a Jurkat-Be cell model. CD55, sCD55, and CD97 were significantly downregulated in CBD PBMCs compared to BeS (P < .001). Serum sCD55 was also reduced in CBD (P < .05). BeSO4 stimulation further downregulated CD55 and upregulated STAT1. CD55 blockade increased TNF-α production and BeLPT responses in CBD (P < .001) and BeS (P < .05); these effects were reversed by JAK2 inhibition. In the Be-cell model, CD55 inhibition enhanced IL-2 production (P < .01), attenuated by JAK2 blockade. These findings suggest that CD55 downregulation amplifies Be-induced immune responses in CBD via JAK2/STAT1 signaling.
- 9 April 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (10) , 1431-1439
Immune Regulation by CD55 in Chronic Beryllium Disease
CD55 is an immune regulator that inhibits T cell activation and also binds to CD97, a molecule involved in immune cell migration and signaling. While CD55 expression is reduced in chronic beryllium disease (CBD), its functional role in disease pathogenesis remains unclear. We hypothesized that CD55 downregulation in peripheral blood mononuclear cells (PBMCs) contributes to heightened beryllium (Be)-specific immune responses in CBD. To test this, we characterized CD55 expression and function in PBMCs from individuals with CBD and beryllium sensitization (BeS), as well as in a human Be-specific T cell model. CD55, sCD55, and CD97 mRNA expression were quantified by qRT-PCR in PBMCs from CBD (n = 25), BeS (n = 36), and control (n = 7) subjects. BeSO4 stimulation was used to assess CD55, STAT1, JAK2, and TNF-α expression over time in CBD PBMCs (n = 8). Serum sCD55 was measured by ELISA in an independent cohort. Functional studies using anti-CD55 neutralizing antibodies and the JAK2 inhibitor TG101348 evaluated effects on TNF-α production and lymphocyte proliferation (BeLPT) in PBMCs, and IL-2 production in a Jurkat-Be cell model. CD55, sCD55, and CD97 were significantly downregulated in CBD PBMCs compared to BeS (P < .001). Serum sCD55 was also reduced in CBD (P < .05). BeSO4 stimulation further downregulated CD55 and upregulated STAT1. CD55 blockade increased TNF-α production and BeLPT responses in CBD (P < .001) and BeS (P < .05); these effects were reversed by JAK2 inhibition. In the Be-cell model, CD55 inhibition enhanced IL-2 production (P < .01), attenuated by JAK2 blockade. These findings suggest that CD55 downregulation amplifies Be-induced immune responses in CBD via JAK2/STAT1 signaling.
- 1 March 2016
- Published by Elsevier in Respiratory Medicine
- Vol. 112, 106-111
The effect of an oral anti-oxidant, N-Acetyl-cysteine, on inflammatory and oxidative markers in pulmonary sarcoidosis
- 1 March 2016
- Published by Elsevier in Respiratory Medicine
- Vol. 112, 106-111
The effect of an oral anti-oxidant, N-Acetyl-cysteine, on inflammatory and oxidative markers in pulmonary sarcoidosis